NCT06555146View on ClinicalTrials.gov

Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy

NANot yet recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

March 31, 2025

Study Completion Date

March 31, 2025

Conditions
Diabetes Mellitus, Type 2Kidney Disease, Chronic
Interventions
DRUG

Semaglutide, 0.5 mg/mL

1 subcutaneous injection on baseline day

DRUG

Placebo, Saline

1 subcutaneous injection on baseline day

Trial Locations (1)

2400

Bispebjerg Hospital, Department of Clinical Physiology & Nuclear Medicine, Copenhagen

All Listed Sponsors
lead

Bispebjerg Hospital

OTHER

NCT06555146 - Semaglutide's Effect on Renal Hemodynamics and Function in Patients With Type 2 Diabetes Mellitus and Nephropathy | Biotech Hunter | Biotech Hunter